

# Marco Rubatto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7997899/publications.pdf>

Version: 2024-02-01

19  
papers

273  
citations

933447

10  
h-index

940533

16  
g-index

20  
all docs

20  
docs citations

20  
times ranked

189  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 157, 250-258.	2.8	52
2	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or SÅ©zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2021, 141, 484-495.	0.7	31
3	The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy. <i>Clinics in Dermatology</i> , 2021, 39, 911-919.	1.6	28
4	Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4561.	4.1	21
5	Risankizumab shows high efficacy and maintenance in improvement of response until week 52. <i>Dermatologic Therapy</i> , 2022, 35, e15378.	1.7	20
6	Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2495-2502.	2.2	19
7	Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficultâ€œtreat population. <i>British Journal of Dermatology</i> , 2022, 187, 263-265.	1.5	16
8	Realâ€œlife comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	16
9	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. <i>Seminars in Oncology</i> , 2020, 47, 302-304.	2.2	15
10	Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience. <i>Cancers</i> , 2021, 13, 6071.	3.7	11
11	Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review. <i>Oncotarget</i> , 2021, 12, 1116-1121.	1.8	9
12	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5475.	2.4	8
13	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097700.	3.2	6
14	Switching from <sc>IL23</sc> inhibitors to <sc>IL17</sc> inhibitors: A safe and effective practice?. <i>Dermatologic Therapy</i> , 2022, 35, .	1.7	6
15	Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit. <i>Future Oncology</i> , 2021, 17, 759-761.	2.4	5
16	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4994.	2.4	4
17	Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study. <i>Dermatologic Therapy</i> , 2022, 35, e15492.	1.7	3
18	SÅ©zary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System. <i>Cells</i> , 2022, 11, 333.	4.1	1

#	ARTICLE	IF	CITATIONS
19	Extensive "œhalo naevi" phenomenon and regression of melanin during nivolumab treatment in metastatic melanoma: A predictor of a better outcome?. <i>Dermatologic Therapy</i> , 2022, 35, e15559.	1.7	1